Live Activity Date: September 23, 2024
Enduring Activity Dates: October 14, 2024 - October 13, 2025

This activity is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer including medical oncologists, thoracic surgeons, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.

Upon completion of this educational activity, participants should be able to: 

• Identify key findings from the most recent clinical trials on early-stage and locally advanced NSCLC presented at WCLC 2024.
• Describe the latest clinical trial results related to driver-negative NSCLC as presented at WCLC 2024.
• Explain the clinical advancements in driver-positive NSCLC based on the newest trials presented at WCLC 2024.

Moderators:

• Clarissa Baldotta, MD, PhD, Medical Oncologist, Institute D'Or for Research and Education, Rio de Janeiro, Brazil
• Hidehito Horinouchi, MD, PhD, Assistant Chief of the Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan

Presenters:

• Patrick Forde, MBBCH, Associate Professor, Johns Hopkins, Department of Oncology, Baltimore, MD, USA
• Xiuning Le, MD, PhD, Associate Professor in the Department of Thoracic and Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
• Jacob Sands, MD, Assistant Professor of Medicine, Harvard Medical School, Lowe Cancer Center for Thoracic Oncology, Dana Farber Cancer Institure, Boston, MA, USA

The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose: 

Full Legal Name	Commercial Interest	Role	Level of Participation in the Activity
Clarissa Baldotta	AstraZeneca	Speaker	Planner/Moderator
	Roche	Speaker
	MSD	Speaker
	Janssen LATAM	Speaker
	Takeda	Speaker
	Daiichi Sando	Speaker
	Pfizer	Speaker
Patrick Forde	AstraZenaca	Research funding/Consultant	Speaker
	BioNTech	Research funding
	BMS	Research funding; Consultant
	Novartis	Research funding
	Regeneron	Research funding/Consultant
	Amgen	Consultant
	Ascendis	Consultant
	Curvac	Consultant
	F Star	Consultant
	Foresight	Consultant
	Forsun	Consultant
	G1	Consultant
	Genelux	Consultant
	Genentech	Consultant
	Gristone	Conslutant
	Iteos	Consultant
	Janssen	Consultant
	Merck	Consultant
	Novocure	Consultant
	Sanofi	Consultant
	Synthekine	Consultant
	Tavotek	Consultant
	Teva	Consultant
	Veracyte	Consultant
Jacob Sands	Abbvie	Consultant	Speaker
	Amgen	Consultant/Research funding
	Astra Zeneca	Consultant
	Boehringer Ingelheim	Consultant
	Curadev	Consultant
	Daiichi-Sankyo	Consultant
	Gilead	Consultant
	Lilly	Consultant
	Medtronic	Consultant
	Pfizer	Consultant
	Pharma Mar	Consultant
	Sanofi	Consultant
	Harpoon	Research funding
Xiuning Le	EMD Serono (Merck KGzA)	Consultant
	Abbvie	Consultant
	AGMEN	Consultant
	Astra Zeneca	Consultant/Speaker/Research funding
	Blueprint Medicines	Consultant
	BMS	Consultant
	Boehringer Ingelheim/Steering Committee	Consultant/Speaker
	Daiichi Sankyo	Consultant
	Eisai	Consultant
	Eli Lilly	Consultant
	GENIUS	Consultant/Speaker
	Gritstone	Consultant
	Hanmi	Consultant
	IMBDx	Consultant/Speaker/Stock
	Janssen R&D	Consultant
	LOXO	Consultant
	Merck KGaA	Consultant/Speaker
	MSD	Consultant/Research funding
	Ono Pharmaceutical	Consultant
	Puma Biotechnology	Consultant
	Roche	Consultant
	Takeda	Consultant
	Spectrum Pharmaceutics	Consultant
	Hengrui Therapeutics	Consultant
	Sensei Biotherapeutics	Consultant
	JNJ	Speaker
	BeiGene	Reserach funding
	Incyte Scientific	Research funding
	Abion	Speaker/Stock
Hidehito Horinouchi	Astra Zeneca	Speaker/Research funding	Planner/Moderator
	Abbvie	Speaker/Research funding
	Roche	Speaker/Research funding
	BMS	Research funding
	Ono	Research funding
	Taiho	Speaker
	MSD	Speaker

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

These relationships with ineligible companies have been mitigated by the International Association for the Stufy of Lung Cancer (IASLC). 

All other presenters, planners, editors, or staff report no relationshops to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

Accreditation Statement: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

Physicians
The International Association for the Study of Lung Cancer designates the live or enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

Countries that accept ACCME-accredited continuing medical education (CME):

The below list includes countries that accept ACCME-accredited continuing medical education (CME). Please note that some countries that accept ACCME-accredited education do not have specific credit requirements for their physicians. 

Antigua & Barbuda
Regulator: Antigua & Barbuda Medical Council

Austria
Regulator: Austrian Academy of Physicians on behalf of the Austrian Medical Chamber

Bahamas
Regulator: Bahamas Medical Council

Belgium
Regulator: Group of Belgian Professional Unions of Specialist Doctors

Bhutan
Regulator: Medical and Health Professional Council, Royal Government of Bhutan

Canada
Regulator: Royal College of Physicians and Surgeons of Canada Maintenance of Certification Program

Croatia
Regulator: Croatian Medical Chamber

Gambia, The
Regulator: The Medical and Dental Council of the Gambia

Germany
Regulator: State Chambers of Physicians in the 16 federal states (only in-person, live events)

India, State of Punjab
Regulator: Punjab Medical Council

Israel
Regulator: Scientific Council, Israeli Medical Association

Jamaica
Regulator: Medical Council of Jamaica

Kuwait
Regulator: Professional Licensing - Ministry of Health

Malawi
Regulator: Medical Council of Malawi

Netherlands, The
Regulator: Royal Dutch Society of the Promotion of Medicine

Oman
Regulator: Oman Medical Specialty Board

Qatar
Regulator: Accreditation Section of the Department of Healthcare Professions of the Qatar Ministry of Public Health

Rwanda
Regulator: Rwanda Medical & Dental Council

Saudi Arabia
Regulator: Saudi Commission for Health Specialties

Singapore
Regulator: Singapore Medical Council

South Africa
Regulator: Health Professions Council of South Africa

Spain
Regulator: Spanish Medical Professional Accreditation Council for CPD/CME

Sri Lanka
Regulator: Sri Lanka Medical Council, Sri Lanka Medical Association, and the Ministry of Health

Sweden
Regulator: Swedish Medical Association

Trinidad & Tobago
Regulator: The Trinidad and Tobago Medical Association

Turkey
Regulator: Turkish Medical Association CME-CPD Accreditation Council

United Arab Emirates, Abu Dhabi
Regulator: Department of Health

United Arab Emirates, Dubai
Regulator: Dubai Health Authority

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

1. Read about the target audience, learning objectives, and author disclosures.
2. Study the educational content online or print it out, if applicable.
3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test.
4. Complete the activity evaluation to provide feedback for future programming and receive credit.

You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.

If you need assistance with this activity, please email: education@iaslc.org.